https://doi.org/10.55788/df679a18
Bilobectomy is the resection of two lobes in the right lung, including the middle lobe. It is a rare procedure and is performed in some cases of right-sided lung cancer, tumour extension, bronchial involvement, or pulmonary artery infiltration, or to avoid the morbidity and mortality of a right pneumonectomy. However, the morbidity and mortality associated with bilobectomy in comparison with other pulmonary resections are not well described. Therefore, investigators retrospectively compared outcomes from bilobectomy with outcomes from both lobectomy and pneumectomy [1].
Patients who underwent elective lobectomy, bilobectomy, or pneumonectomy for lung cancer between 2009 and 2017, excluding reoperations, were identified in the Society for Thoracic Surgeons General Thoracic Surgery Database. The primary outcome of the analysis was 30-day peri-operative mortality. Secondary outcomes included 30-day morbidity and mortality of upper versus lower bilobectomy. Dr Andrew Li (Yale School of Medicine, CT, USA) presented the results [1].
A total of 2,911 bilobectomy, 65,506 lobectomy, and 3,024 pneumonectomy patients were included in the analysis. The 30-day peri-operative mortality of bilobectomy was not significantly different from left pneumonectomy (HR 1.31; P=0.10). The 30-day peri-operative mortality of bilobectomy was significantly worse than that of left or right lobectomy (HR 0.44 and HR 0.47, respectively; both P<0.01) but better than that of right pneumonectomy (HR 2.76; P<0.01). Bilobectomy had the same 30-day post-operative morbidity as pneumonectomy (49.8% vs 48.0%), while 30-day post-operative morbidity in lobectomy patients was 38%. Bilobectomy had the highest rate of pneumonia of all procedures (7.5%).
Of note, upper bilobectomy patients (5 segments involved) fared better than lower bilobectomy patients (7 segments involved). In fact, survival in lower bilobectomy patients closely mirrored the survival in left pneumonectomy patients.
Based on these results, Dr Li concluded that peri-operative mortality of bilobectomy is worse than that of lobectomy and more comparable with that of left pneumonectomy. However, as survival of bilobectomy is superior to that of right pneumonectomy, it spares patients the increased risks of right pneumonectomy.
- Li A, et al. Respect the middle lobe: Perioperative survival of bilobectomy compared to lobectomy and pneumonectomy. Abstract 109MO. ELCC 2022 Virtual Meeting, 30 March–02 April.
Copyright ©2022 Medicom Medical Publishers
Posted on
Previous Article
« Pro-inflammatory tumour profile predicts complete pathological response to neoadjuvant chemoimmunotherapy Next Article
Promising efficacy of neoadjuvant osimertinib in EGFR-mutated NSCLC »
« Pro-inflammatory tumour profile predicts complete pathological response to neoadjuvant chemoimmunotherapy Next Article
Promising efficacy of neoadjuvant osimertinib in EGFR-mutated NSCLC »
Table of Contents: ELCC 2022
Featured articles
Early-Stage Non-Small Cell Lung Cancer
Real-world treatment and survival in early-stage NSCLC
Consistent efficacy of osimertinib in Chinese and global population
Promising efficacy of neoadjuvant osimertinib in EGFR-mutated NSCLC
Peri-operative survival in bilobectomy is comparable with that of left pneumonectomy
Advanced Non-Small Cell Lung Cancer
Pro-inflammatory tumour profile predicts complete pathological response to neoadjuvant chemoimmunotherapy
Furmonertinib outperforms gefitinib as first-line therapy in patients with EGFR-mutated NSCLC
Second-line oritinib demonstrated potential clinical benefit in advanced EGFR-mutated NSCLC
Updated results confirm efficacy and safety of entrectinib in patients with NTRK fusion-positive NSCLC
ROS1 rearrangement-targeting unecritinib is a potential new first-line strategy
Savolitinib is effective in patients with MET-mutated NSCLC
Sintilimab plus chemotherapy improves OS in treatment-naïve, stage III–IV non-squamous NSCLC
Updated results of CameL-sq trial confirm benefit of camrelizumab
No long-term benefit of adding ipilimumab to pembrolizumab in metastatic NSCLC
In concurrent CRT for stage III, unresectable NSCLC, performance status is better with proton therapy than photon therapy
No improved prognosis for concurrent versus sequential immune checkpoint inhibition and CRT in unresectable NSCLC
Durvalumab after sequential CRT safe in stage III, unresectable NSCLC
No impact of grade ≥2 pneumonitis on patient-reported outcomes in PACIFIC
Immunotherapy delays deterioration in health-related quality of life in metastatic NSCLC
Small Cell Lung Cancer
Total metabolic tumour volume: a new potential prognostic factor in SCLC
Radiation dose on oesophagus predicts OS in SCLC patients treated with chemoradiotherapy
Characteristics of long-term survivors in the CASPIAN trial
Outcomes of real-world CANTABRICO trial match results from CASPIAN
Lung Cancer Epidemiology
Lung cancer diagnosis with liquid biopsy of peripheral blood cells
Rare EGFR mutations as oncogenic drivers
Decline in lung cancer mortality is almost exclusive to men
Related Articles
January 29, 2021
Lung-cancer salvage surgery might help after TKI treatment
September 21, 2021
Discrepancies and lack of guideline adherence in EGFR+ NSCLC treatment
© 2023 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy